Abstract
We compared the outcome of concomitant chemoradiotherapy using two different schedules of cisplatin, 100mg/m2 or 80mg/m2 cisplatin once every 3 weeks (3-Weekly) and 40mg/m2 cisplatin once per week (Weekly), for patients with previously untreated squamous cell carcinoma of the head and neck. From November 2007 to March 2015, 34 patients with previously untreated squamous cell carcinoma of the head and neck were included in this study. Twenty-six received 3-Weekly cisplatin, and 8 received Weekly cisplatin. 65% of patients in the 3-Weekly group and 88% of those in the Weekly group received a total cisplatin dose of more than 200mg/m2. In patients 75 years old and over, no patients in the 3-Weekly group and 75% of those in the Weekly group received a total cisplatin dose of more than 200mg/m2. Weekly cisplatin treatment can achieve higher compliance compared to 3-Weekly cisplatin treatment in patients with older age at diagnosis.
